Similarly, clinical trials targeting SX-682, a small-molecule inhibitor of CXCR1 and CXCR2 in combination with pembrolizumab (anti-PD-1 immunotherapy), are undergoing for metastatic or recurrent stage IIIC or IV non-small cell lung cancer [NCT05570825], metastatic melanoma [NCT03161431], and metastatic colorectal cancer (mCRC) [NCT06149481]. This evidence concerns the gene CXCR2 and metastatic colorectal cancer.